InMed Pharmaceuticals: Edison Open House Healthcare 2022

InMed Pharmaceuticals is a pharmaceutical company focused on developing and manufacturing cannabinoids. Its main pipeline product is INM-755 for EB, a serious, debilitating orphan indication.

• What are rare-cannabinoids?
• What is InMed’s business model and why does it focus on rare cannabinoids?
• Tell us about the acquisition of BayMedica and what the combined company looks like.
• With the acquisition of BayMedica, where does InMed fit into the manufacture of rare cannabinoids? Where do you have a competitive advantage?
• What is the status of your pharmaceutical pipeline?
• What milestones can investors expect over the next six to 12 months